YU11896A - Benzotiofenska jedinjenja, intermedijeri, kompozicije koje ih sadrže - Google Patents

Benzotiofenska jedinjenja, intermedijeri, kompozicije koje ih sadrže

Info

Publication number
YU11896A
YU11896A YU11896A YU11896A YU11896A YU 11896 A YU11896 A YU 11896A YU 11896 A YU11896 A YU 11896A YU 11896 A YU11896 A YU 11896A YU 11896 A YU11896 A YU 11896A
Authority
YU
Yugoslavia
Prior art keywords
alkyl
compounds
formula
pyrrolidinyl
protecting group
Prior art date
Application number
YU11896A
Other languages
English (en)
Inventor
David Palkowitz Alan
Jeff Thrasher Kenneth
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/396,401 external-priority patent/US5510357A/en
Priority claimed from US08/552,564 external-priority patent/US5998441A/en
Priority claimed from US08/552,890 external-priority patent/US5919800A/en
Priority claimed from US08/554,223 external-priority patent/US5856340A/en
Priority claimed from US08/552,679 external-priority patent/US5856339A/en
Priority claimed from US08/552,565 external-priority patent/US5977093A/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU11896A publication Critical patent/YU11896A/sh
Publication of RS49886B publication Critical patent/RS49886B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dati pronalazak daje farmaceutski aktivna jedinjenja formule I u kojoj, R1 je -H, -OH, -O(C1-C4 alkil), -OCOC6H5, -OCO(C1-C6 alkil), ili -OSO(C2-C6 alkil); R2 je -H, -OH, -O(C1-C4 alkil), -OCOC6H5, -OCO(C1-C6 alkil), ili -OSO(C2-C6 alkil) ili halogen; R3 je 1-piperidinil, 1-pirolidinil, metil-1-pirolidinil, dimetil-1-pirolidinil, 4-morfolino, dimetilamino, dietilamino, diizopropilamino, ili 1-heksametilenaimino; n je 2 ili 3; i z je -O- ili -S-; ili njihovu farmaceutski prihvatljivu so. Takođe su data jedinjnja formule II R1a je -H ili -OR7a, pri čemu R7a je -H ili hidroksi zaštitna grupa; R2a je -H, halogen, ili -OR8a u kojem R8a je -H ili hidroksi zaštitna grupa; R6 je -H, ili hidroksi zaštitna grupa koji se može selektivno ukloniti; Z je -O- ili -S-; ili njihova farmaceutski prihvatljiva so, koji su korisni intermedijari za dobijanje jedinjenja formule I. Dalje su obezbeđene farmaceutske kompozicije jedinjenja formule I i postupci upotrebe jedinjenja formule I, za, inter alia, ublažavanje simptoma post menopauznog sindroma i hormonalno zavisnog kancera, posebno kancera dojki.
YUP-118/96A 1995-02-28 1996-02-27 Benzotiofenska jedinjenja, intermedijari, kompozicije i metode RS49886B (sr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US08/396,401 US5510357A (en) 1995-02-28 1995-02-28 Benzothiophene compounds as anti-estrogenic agents
US55276095A 1995-11-03 1995-11-03
US08/552,636 US5723474A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods
US08/552,564 US5998441A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods
US08/552,890 US5919800A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods
US08/554,223 US5856340A (en) 1995-02-28 1995-11-03 Method of treating estrogen dependent cancers
US08/552,679 US5856339A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods
US08/552,565 US5977093A (en) 1995-02-28 1995-11-03 Benzothiophene compounds, intermediates, compositions, and methods

Publications (2)

Publication Number Publication Date
YU11896A true YU11896A (sh) 1998-12-23
RS49886B RS49886B (sr) 2008-08-07

Family

ID=27569747

Country Status (4)

Country Link
KR (1) KR100446895B1 (sh)
MY (1) MY115721A (sh)
NZ (1) NZ286079A (sh)
RS (1) RS49886B (sh)

Also Published As

Publication number Publication date
RS49886B (sr) 2008-08-07
MY115721A (en) 2003-08-30
KR960031454A (ko) 1996-09-17
KR100446895B1 (ko) 2006-04-10
NZ286079A (en) 1997-12-19

Similar Documents

Publication Publication Date Title
YU11496A (sh) Naftilna jedinjenja, njihove farmaceutske formulacije i intermedijari i postupak za njihovo dobijanje
PT703228E (pt) Compostos de naftilo intermediarios processos composicoes que os envolvem
GEP20084496B (en) Benzothiophene compound, intermediate, composition, and method
AR003930A1 (es) Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
MX9800800A (es) Compuestos, intermedios de naftilo y dihidronaftilo, composiciones y metodos.
TW372969B (en) Pharmaceutical composition for minimizing bone loss
ATE253567T1 (de) Benzofuranverbindungen, präparate und verfahren
KR970705999A (ko) 타목시펜 및 타목시펜 유사체의 자궁향성 효과를 최소화시키는 방법 (a method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs)
YU11896A (sh) Benzotiofenska jedinjenja, intermedijeri, kompozicije koje ih sadrže
PT832881E (pt) Compostos de benzofluoreno intermediarios composicoes e metodos
YU34296A (sh) Upotreba jedinjenja za pripremanje leka i njegova farmaceutska smeša
CA2170479A1 (en) Benzothiophene compounds, intermediates, compositions, and methods
MXPA05003166A (es) Derivados de dihidro-dibenzo (a) antracenos y su uso como modulares de receptores de estrogenos selectivos.
TW349096B (en) Benzothiophene compounds, intermediates, compositions, and methods
CO4940502A1 (es) Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos